Case 2: Safety Considerations in the Use of T-DXd for HER2+ mBC
A key opinion leader in oncology shares expert perspectives on safety considerations when treating patients with T-DXd in the second-line setting for HER2+ mBC.
Case 2: Second-line Treatment Selection for Metastatic HER2+ BC
Emphasizing the variety of options available in the second-line setting, Chau T. Dang, MD, remarks on the case of a patient with HER2+ mBC and highlights key factors affecting therapeutic decision-making.
Case 1: Subcutaneous vs Intravenous Trastuzumab/Pertuzumab
An expert in breast cancer considers the role of intravenous and fixed-dose subcutaneous formulations of trastuzumab/pertuzumab as studied in the FeDeriCa and PHranceSCa clinical trials.
Case 1: Risk Assessment and Treatment Selection in Early-stage HER2+ BC
Chau T. Dang, MD, considers the case of a patient with early-stage HER2+ BC and discusses risk assessment and factors to consider when selecting between neoadjuvant and adjuvant treatment.
The Future of HER2+ Breast Cancer Treatment
Chau Dang, MD, medical oncologist, chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the future of HER2+ breast cancer treatment.
2 Commerce Drive Cranbury, NJ 08512